Cord blood CAR-T for B-cell ALL
Part of Blood & lymphatic, Cancer, Immune system & allergy, Infections clinical trials.
This study tests a new type of CAR-T therapy made from donated cord blood cells to treat B-ALL. The goal is to see if it can help when other treatments haven't worked or aren't an option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have been diagnosed with B-cell acute lymphoblastic leukemia that has the CD19 or CD20 marker on the cells.
- You have reasonable kidney, liver, and heart function.
- You haven't had a severe reaction to a previous CAR-T therapy.
- You do not have active leukemia in your brain or spinal cord.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial tests a personalized cancer treatment using your own immune cells (called CAR T-cells) to target and kill leukemia cells that have a specific marker (CD19). It may be an option for adults with B-cell acute lymphoblastic leukemia (B-ALL) who haven't had this type of therapy before.
This trial tests whether CAR-T cells made from a healthy donor can help treat B-cell acute lymphoblastic leukemia that has come back or not responded to treatment. It's for adults who cannot use their own cells for CAR-T therapy.
This trial tests a personalized cell therapy (CAR-T) for people with B-cell acute lymphoblastic leukemia (ALL) that has come back after treatment or is hard to treat. The therapy uses your own immune cells, modified to find and kill leukemia cells.
This trial uses a one-time infusion of specially grown immune cells (CAR T cells) from a healthy donor to attack leukemia that has come back or not responded to prior treatments. It is for children and young adults with B-cell acute lymphoblastic leukemia that still shows the CD19 marker.
This trial tests a new type of CAR T cell therapy that targets two proteins (CD19 and CD22) found on leukemia cells. It is for children and young adults whose B-ALL has come back multiple times, or who have not responded to other treatments.
This trial tests a CAR-T cell therapy for adults who have just been diagnosed with a type of leukemia called Ph+ B-cell ALL. The treatment uses specially engineered immune cells to target and destroy cancer cells that have a specific marker (CD19 and CD22) and the Philadelphia chromosome. It may be an option for those who have not yet started standard chemotherapy.
Hear when a new B-Cell Acute Lymphoblastic Leukemia, Adult trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.